4.5 Article

Genome-wide methylotyping resolves breast cancer epigenetic heterogeneity and suggests novel therapeutic perspectives

Journal

EPIGENOMICS
Volume 11, Issue 6, Pages 605-617

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/epi-2018-0213

Keywords

5-fluorouracil; adenylate cyclase pathway; breast cancer; cancer cell lines; DNA methylation; DNA methylotype; leukotriene receptors; reduced representation bisulfite sequencing; resveratrol; XmaI-RRBS

Funding

  1. Russian Science Foundation [18-15-00430]
  2. Russian Science Foundation [18-15-00430] Funding Source: Russian Science Foundation

Ask authors/readers for more resources

Aim: To provide a breast cancer (BC) methylotype classification by genome-wide CpG islands bisulfite DNA sequencing. Materials & methods: XmaI-reduced representation bisulfite sequencing DNA methylation sequencing method was used to profile DNA methylation of 110 BC samples and 6 normal breast samples. Intrinsic DNA methylation BC subtypes were elicited by unsupervised hierarchical cluster analysis, and cluster-specific differentially methylated genes were identified. Results & conclusion: Overall, six distinct BC methylotypes were identified. BC cell lines constitute a separate group extremely highly methylated at the CpG islands. In turn, primary BC samples segregate into two major subtypes, highly and moderately methylated. Highly and moderately methylated superclusters, each incorporate three distinct epigenomic BC clusters with specific features, suggesting novel perspectives for personalized therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available